Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review

Indivior has begun implementing a cost-cutting plan that includes workforce reductions and a review of its real-estate footprint as part of a multi-year restructuring effort52.

The plan follows a sharp cut to its 2025 sales and profit guidance, with expected full-year revenue to fall nearly 20% to a range between $955 million and $1.02 billion, and adjusted operating profit possibly dropping between 27% and 40%1.

The restructuring is partly a response to increasing competition in the U.S. from generic drug manufacturers, which is accelerating market share declines for key products15.

Headcount reductions are already underway, with layoffs confirmed in public layoff trackers and company announcements25.

The company is also considering divestiture of assets such as Opvee and may undergo further changes as restructuring progresses5.

Recent job cuts also stem from previous product discontinuations—for example, the earlier discontinuation of its schizophrenia drug Perseris in 2024 led to 130 layoffs1.

Indivior is scheduled to report second quarter 2025 financial results and discuss further restructuring details on July 31, 20254.

Sources:

1. https://www.sharesmagazine.co.uk/news/shares/indivior-slashes-2025-sales-and-profit-guidance

2. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025

4. https://www.biospace.com/press-releases/indivior-to-report-second-quarter-2025-financial-results-and-host-webcast-on-july-31st

5. https://www.fiercepharma.com/pharma/indivior-slims-headcount-weighs-opvee-divesture-phase-1-multi-year-restructuring-plan